<DOC>
	<DOC>NCT02970318</DOC>
	<brief_summary>This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).</brief_summary>
	<brief_title>A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Men and women ≥ 18 years of age. ECOG performance status of 0 to 2. Diagnosis of CLL Active disease meeting ≥ 1 of the IWCLL 2008 criteria for requiring treatment. Meet the following laboratory parameters: ANC ≥ 750 cells/μL or ≥ 500 cells/μL in subjects with documented bone marrow involvement, and independent of growth factor support 7 days before assessment. Platelet count ≥ 50,000 cells/μL or ≥ 30,000 cells/μL in subjects with documented bone marrow involvement, and without transfusion support 7 days before assessment. AST and ALT ≤ 2.0 x upper limit of normal Total bilirubin ≤ 1.5 x ULN. Estimated creatinine clearance of ≥ 30 mL/min Received ≥ 1 prior systemic therapies for CLL. Received any chemotherapy, external beam radiation therapy, anticancer antibodies, or investigational drug within 30 days before first dose of study drug. Prior radio or toxinconjugated antibody therapy. Major surgery within 30 days of first dose of study drug. Prior malignancy, except for adequately treated lentigo maligna melanoma, nonmelanomatous skin cancer, carcinoma in situ or other malignancy treated with no evidence of active disease &gt; 2 years before Screening and at low risk for recurrence. Significant cardiovascular disease within 6 months of screening. Known history of infection with HIV. History of or ongoing druginduced pneumonitis. History of stroke or intracranial hemorrhage within 6 months before first dose of study drug. History of bleeding diathesis. Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists within 7 days of first dose of study drug. Requires treatment with a strong CYP3A inhibitor/inducer.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>CLL</keyword>
	<keyword>BTK</keyword>
	<keyword>Bruton Tyrosine Kinase</keyword>
	<keyword>acalabrutinib</keyword>
	<keyword>ACP-196</keyword>
</DOC>